Although ivosidenib is selectively used to cure cancer patients carrying IDH1 mutations, it still exerts a suppressive function on cancer cells with normal IDH1 [34], which implies that ivosidenib has a secondary intracellular target beyond mutant-IDH1-mediated metabolic regulation. The gene discussed is IDH1; the disease is cancer.